Allogeneic Mesenchymal Stem Cells in Osteoarthritis

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Stempeutics Research Pvt Ltd
ClinicalTrials.gov Identifier:
NCT01453738
First received: October 13, 2011
Last updated: November 24, 2012
Last verified: November 2012
  Purpose

This trial is planed to study if allogeneic mesenchymal stem cells would be safe and beneficial in osteoarthritis of knee joint. This is a double blind study. Different doses of stem cells will be used in this study.


Condition Intervention Phase
Osteoarthritis of Knee
Biological: Ex- vivo cultured adult allogeneic MSCs
Biological: Plasmalyte-A
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double Blind, Multicentric, Placebo Controlled, Phase -II Study Assessing the Safety and Efficacy of Intraarticular Ex-vivo Cultured Adult Allogeneic Mesenchymal Stem Cells in Patients With Osteoarthritis of Knee

Resource links provided by NLM:


Further study details as provided by Stempeutics Research Pvt Ltd:

Primary Outcome Measures:
  • Number and percentage of patients with adverse events as a measure of safety and tolerability [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
    • Safety evaluation will include assessment of physical examination, periodic monitoring of vital signs (heart rate, respiratory rate, blood pressure and temperature), clinical laboratory investigations (including haematology, serum chemistry, LFT, urine-analysis) and 12-lead ECG recording.
    • Tolerability: Adverse events monitored using information volunteered by the patients and as observed by the PI will be summarized descriptively by total number of AE(s) and compared between the study arms.


Secondary Outcome Measures:
  • Change from baseline in the WOMAC OA (Western Ontario and McMaster Universities Osteoarthritis) Index -pain subscale score [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Change from baseline in WOMAC OA stiffness index [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Change from baseline in WOMAC OA composite index [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Change from baseline in ICOAP (Intermittent and Constant Osteoarthritis Pain) [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Change from baseline in radiographic (X-ray) findings of knee [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Change from baseline in the WORMS score (Whole-Organ Magnetic Resonance Imaging Score) of knee using MRI [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Change from baseline in arthritis pain scores on the visual analogue scale [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Reduction in the intake of analgesic tablets from baseline [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 60
Study Start Date: November 2011
Estimated Study Completion Date: July 2014
Estimated Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ex- vivo cultured adult allogeneic MSCs
Single intraarticular dose of allogeneic MSCs suspended in 2-4ml Plasmalyte A followed by 2 ml of Hyaluronan
Biological: Ex- vivo cultured adult allogeneic MSCs
Single intraarticular dose of allogeneic MSCs suspended in 2ml Plasmalyte followed by 2ml of Hyaluronan
Placebo Comparator: Plasmalyte-A
Single intraarticular dose of 2ml Plasmalyte
Biological: Plasmalyte-A
Single intraarticular dose of 2ml Plasmalyte followed by 2ml Hyaluronan

  Eligibility

Ages Eligible for Study:   40 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Males or females in the age 40 - 70 years (both inclusive)
  2. Radiographic evidence of grade 2 to 3 osteoarthritis based on the Kellgren and Lawrence radiographic criteria.
  3. History of primary idiopathic osteoarthritis of the knee characterized by pain which requires intake of analgesics.
  4. Self-reported difficulty in at least one of the following activities attributed to knee pain: lifting and carrying groceries, walking 400 metres, getting in and out of a chair, or going up and down stairs.
  5. Patients who have been on stable medication which may be NSAIDs / Opioid or opiate analgesics, for the past three months.
  6. Female patients of childbearing age must be willing to use accepted methods of contraception during the course of the study
  7. Ability to provide written informed consent.

Exclusion Criteria:

  1. Prior or ongoing medical conditions (e.g., concomitant illness, psychiatric condition, alcoholism, drug abuse), medical history, physical findings, ECG findings, or laboratory abnormality that, in the investigator's opinion, could adversely affect the safety of the subject, makes it unlikely that the course of treatment or follow-up would be completed, or could impair the assessment of study results.
  2. History of surgery, or major trauma to the study joint
  3. Arthroscopy on the study joint in the previous 12 months
  4. Signs of active study joint inflammation including redness, warmth, and/or, if qualifying with osteoarthritis of the knee, a large, bulging effusion of the study knee joint with the loss of normal contour of the joint at the screening visit or at the baseline examination
  5. Patients who had received intraarticular steroids or hyaluronan within the last three months.
  6. Infections in or around the knee.
  7. Patients awaiting a replacement knee or hip joint
  8. Patients with other conditions that cause pain
  9. Patients with deformity of the knee joint.
  10. Significantly incapacitated or disabled and would be categorized as ACR Functional Class IV (largely or wholly incapacitated), or unable to walk without assistive devices
  11. Patients with other known rheumatic or inflammatory disease such as rheumatoid arthritis
  12. Other pathologic lesions on x-rays of knee
  13. Positive hepatitis B surface antigen, hepatitis C antibody test, Anti human immunodeficiency virus (HIV) antibody test, or RPR
  14. History of Bleeding disorders
  15. Known hypersensitivity to Hyaluronan products or animal sera
  16. For women of child-bearing potential: positive pregnancy test or lactating [Females who are planning pregnancy within next one year should be excluded]
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01453738

Locations
India
Department of Orthopedics, M. S. Ramaiah Memorial Hospital
Bangalore, Karnataka, India, 560054
Department of Orthopedics, Kasturba Medical College
Manipal, Karnataka, India, 576 104
Seth G. S. Medical College and KEM Hospital
Mumbai, Maharashtra, India, 400012
Jehangir Hospital
Pune, Maharashtra, India, 411001
Department of Immunology Sanjay Gandhi Post Graduate Institute of Medical Sciences
Lucknow, Uttar Pradesh, India, 226 014
Sponsors and Collaborators
Stempeutics Research Pvt Ltd
Investigators
Principal Investigator: Vikas Agarwal, MD., DM Department of Immunology Sanjay Gandhi Post Graduate Institute of Medical Sciences
Principal Investigator: Vivek Pandey, MS Department of Orthopedics, Kasturba Medical College
Principal Investigator: Naresh Shetty, MS Department of Orthopedics, M. S. Ramaiah Memorial Hospital
Principal Investigator: Shrikant Wagh, MD Jehangir Hospital
Principal Investigator: Bhibas Dasgupta, MS Seth G. S. Medical College and KEM Hospital
  More Information

No publications provided

Responsible Party: Stempeutics Research Pvt Ltd
ClinicalTrials.gov Identifier: NCT01453738     History of Changes
Other Study ID Numbers: SRPL/OA/09-10/001
Study First Received: October 13, 2011
Last Updated: November 24, 2012
Health Authority: India: Drugs Controller General of India

Keywords provided by Stempeutics Research Pvt Ltd:
Osteoarthritis
Knee
Stem cells
Mesenchymal Stem Cells

Additional relevant MeSH terms:
Osteoarthritis
Osteoarthritis, Knee
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Plasma-lyte 148
Ophthalmic Solutions
Pharmaceutical Solutions
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on August 26, 2014